Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;34(3):e14930.
doi: 10.1111/dth.14930. Epub 2021 Mar 14.

Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role?

Lorenza Burzi  1 , Federica Repetto  1 , Alice Ramondetta  1 , Giulia Rozzo  1 , Matteo Licciardello  1 , Simone Ribero  1 , Pietro Quaglino  1 , Paolo Dapavo  1
Affiliations

Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role?

Lorenza Burzi et al. Dermatol Ther. 2021 May.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Dequidt L, Cogrel O, Guillet S, et al. Paradoxical psoriasiform reactions to antitumour necrosis factor-α drugs in hidradenitis suppurativa. Br J Dermatol. 2018;178(1):281-283.
    1. Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401-1409. https://doi.org/10.1111/bjd.15748.
    1. Casseres RG, Kahn JS, Her MJ, Rosmarin D. Guselkumab in the treatment of hidradenitis suppurativa: a retrospective chart review. J Am Acad Dermatol. 2019;81(1):265-267.
    1. Kearney N, Byrne N, Kirby B, Hughes R. Successful use of guselkumab in the treatment of severe hidradenitis suppurativa. Clin Exp Dermatol. 2020;45(5):618-619.
    1. Garcia-Melendo C, Vilarrasa E, Cubiró X, Bittencourt F, Puig L. Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab. Dermatol Ther. 2020;33(6):e14180.

MeSH terms

LinkOut - more resources